Printer Friendly

Titan Pharmaceuticals discussing U.S. Probuphine commercialization with Braeburn.

Titan Pharmaceuticals (TTNP) confirmed that it and Braeburn Pharmaceuticals (BBRX) are in discussions regarding their partnership for the development and commercialization of Probuphine, the first 6-month maintenance treatment of opioid dependence. Braeburn's receipt of a Complete Response Letter from the U.S. FDA regarding the New Drug Application for its injectable buprenorphine product is likely to negatively impact Braeburn's Probuphine marketing activities as it focuses on addressing the CRL. Titan has been in preliminary discussions with Braeburn for the return of U.S. commercialization rights to Probuphine and believes it is now appropriate to seek a new partner that can better focus on a successful commercialization strategy for Probuphine. Titan has retained Canaccord Genuity to assist in this effort as part of an evaluation of strategic and financial alternatives.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Jan 22, 2018
Words:129
Previous Article:Oil Action: WTI benchmark futures are fractionally lower.
Next Article:Regeneron reports approval of Dupixent in Japan for atopic dermatitis.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters